[1]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073-1077.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
　WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(8):1073-1077.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
点击复制

生长分化因子-15在心房颤动中的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2019年8期
页码:
1073-1077
栏目:
综述
出版日期:
2019-11-25

文章信息/Info

Title:
Growth Differentiation Factor-15 in Development of Atrial Fibrillation
作者:
韦莹 刘书旺 李蕾 崔鸣
(北京大学第三医院心内科、血管医学研究所,国家卫生健康委心血管分子生物学与调节肽重点实验室,分子心血管学教育部重点实验室,心血管受体研究北京市重点实验室,北京100191)
Author(s):
WEI Ying; LIU Shuwang; LI Lei; CUI Ming
(Department of Cardiology and Institute of Vascular Medicine,Peking University Third Hospital;NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides;Key Laboratory of Molecular Cardiovascular Science,Ministry of Education;Beijing Key Laboratory of Cardiovascular Receptors Research. Beijing 100191,China )
关键词:
生长分化因子-15; 心房颤动; 心血管疾病
Keywords:
Growth differentiation factor 15; Atrial fibrillation; Cardiovascular diseases
DOI:
10.16806/j.cnki.issn.1004-3934.2019.08.001
摘要:
生长分化因子-15（GDF-15）是转化生长因子-β（TGF-β）超家族成员的一种应激蛋白，已证实是冠心病、心力衰竭等心血管疾病的标志物。近年研究发现GDF-15在心房颤动人群中表达升高，并对预后具有一定预测作用；然而，具体作用和机制未明。现对GDF-15在心房颤动发生和发展的研究进展做一综述。
Abstract:
Growth differentiation factor 15(GDF-15) is a stress-responsive protein that belongs to the super family of transforming growth factor β.It has been proved to be a biomarker in cardiovascular diseases,such as coronary heart disease and heart failure. Recently,the GDF-15 concentrations were reported to be higher in patients with atrial fibrillation,and can possibly be used as its prognostic indicator. But the specific mechanisms remain unclear.In this article,we review the recent studies that discussed the research advancement of GDF-15 in the development of atrial fibrillation

参考文献/References:

[1]Yang H,Filipovic Z,Brown D,et al. Macrophage inhibitory cytokine-1:a novel biomarker for p53 pathway activation[J]. Mol Cancer Ther,2003,2(10):1023-1029.
[2]Xu X,Li Z,Gao W. Growth differentiation factor 15 in cardiovascular diseases:from bench to bedside[J]. Biomarkers,2011,16(6):466-475.
[3]Corre J,Hébraud B,Bourin P. Concise review:growth differentiation factor 15 in pathology:a clinical role?[J]. Stem Cells Transl Med,2013,2(12):946-952.
[4]Wollert KC,Kempf T,Wallentin L. Growth differentiation factor 15 as a biomarker in cardiovascular disease[J]. Clin Chem,2017,63(1):140.
[5]Kempf T,Eden M,Strelau J,et al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury[J]. Circ Res,2006,98(3):351-360.
[6]de Jager SC,Bermúdez B,Bot I,et al. Growth differentiation factor 15 deficiency protects against atherosclerosis by attenuating CCR2-mediated macrophage chemotaxis[J]. J Exp Med,2011,208(2):217-225.
[7]Johnen H,Kuffner T,Brown DA,et al. Increased expression of the TGF-b superfamily cytokine MIC-1/GDF15 protects ApoE(-/-) mice from the development of atherosclerosis[J]. Cardiovasc Pathol,2012,21(6):499-505.
[8]Bonaterra GA,Zugel S,Thogersen J,et al. Growth differentiation factor-15 deficiency inhibits atherosclerosis progression by regulating interleukin-6-dependent inflammatory response to vascular injury[J]. J Am Heart Assoc,2012,1(6):e002550.
[9]Wollert KC,Kempf T,Peter T,et al.Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome[J].Circulation,2007,115(8):962-971.[10]Kempf T,von Haehling S,Peter T,et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure[J]. J Am Coll Cardiol,2007,50(11):1054-1060.[11]Cotter G,Voors AA,Prescott MF,et al. Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure:results from the RELAX-AHF study[J]. Eur J Heart Fail,2015,17(11):1133-1143.
[12]Lind L,Wallentin L,Kempf T,et al. Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly:results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study[J]. Eur Heart J,2009,30(19):2346 -2353.
[13]Hu D,Sun Y. Epidemiology,risk factors for stroke,and management of atrial fibrillation in China[J]. J Am Coll Cardiol,2008,52(10):865-868.
[14]杨江琴,刘艳. 中老年心房颤动患者合并认知功能障碍的机制及诊疗进展[J]. 心血管病学进展,2019,40(1):73-76.
[15]Begg GA,Holden AV,Lip GY,et al. Assessment of atrial fibrosis for the rhythm control of atrial fibrillation[J]. Int J Cardiol,2016,220:155-161.
[16]Dzeshka MS,Lip GY,Snezhitskiy V,et al. Cardiac fibrosis in patients with atrial fibrillation:mechanisms and clinical implications[J]. J Am Coll Cardiol,2015,66(8):943-959.
[17]Khan R,Sheppard R. Fibrosis in heart disease:understanding the role of transforming growth factor-β1 in cardiomyopathy,valvular disease and Arrhythmia[J]. Immunology,2006,118(1):10-24.
[18]Xu XY,Nie Y,Wang FF,et al. Growth differentiation factor (GDF)-15 blocks norepinephrine-induced myocardial hypertrophy via a novel pathway involving inhibition of epidermal growth factor receptor transactivation[J]. J Biol Chem,2014,289(14):10084-10094.
[19]Xu J,Kimball TR,Lorenz JN,et al. GDF15/MIC-1 functions as a protective and anti-hypertrophic factor released from the myocardium in association with SMAD protein activation[J]. Circ Res,2006,98(3):342-350.
[20]Heger J,Schiegnitz E,von Waldthausen D,et al. Growth differentiation factor 15 acts anti-apoptotic and pro-hypertrophic in adult cardiomyocytes[J]. J Cell Physiol,2010,224(1):120-126.
[21]Hijazi Z,Verdecchia P,Oldgren J,et al. Cardiac biomarkers and left ventricular hypertrophy in relation to outcomes in patients with atrial fibrillation:experiences from the RE-LY trial[J]. J Am Heart Assoc,2019,8(2):e010107.
[22]Zhou YM,Li MJ,Zhou YL,et al. Growth differentiation factor-15 (GDF-15),novel biomarker for assessing atrial fibrosis in patients with atrial fibrillation and rheumatic heart disease[J]. Int J Clin Exp Med,2015,8(11):21201-21207.
[23]Montoro-García S,Hernández-Romero D,Jover E,et al. Growth differentiation factor-15,a novel biomarker related with disease severity in patients with hypertrophic cardiomyopathy[J]. Eur J Intern Med,2012,23(2):169-174.
[24]Bening C,Mazalu EA,Yaqub J,et al. Atrial contractility and fibrotic biomarkers are associated with atrial fibrillation after elective coronary artery bypass grafting[J]. J Thorac Cardiovasc Surg,2019, pii: S0022-5223(19)30515-X.?
[25]Shao Q,Liu H,Ng CY,et al. Circulating serum levels of growth differentiation factor-15 and neuregulin-1 in patients with paroxysmal non-valvular atrial fibrillation[J]. Int J Cardiol,2014,172(2):311-313.
[26]Doulamis IP,Samanidis G,Tzani A,et al. Proteomic profile of patients with atrial fibrillation undergoing cardiac surgery[J]. Interact Cardiovasc Thorac Surg,2019,28(1):94-101.
[27]Lind L,Sundstr?m J,Stenemo M,et al. Discovery of new biomarkers for atrial fibrillation using a custom-made proteomics chip[J]. Heart,2017,103(5):377-382.
[28]Svennberg E,Lindahl B,Berglund L,et al. NT-proBNP is a powerful predictor for incident atrial fibrillation—Validation of a multimarker approach[J]. Int J Cardiol,2016,223:74-81.
[29]Rienstra M,Yin X,Larson MG,et al. Relation between soluble ST2,growth differentiation factor-15,and high-sensitivity troponin I and incident atrial fibrillation[J]. Am Heart J,2014,167(1):109-115.
[30]Wallentin L,Hijazi Z,Andersson U,et al. Growth differentiation factor 15,a marker of oxidative stress and inflammation,for risk assessment in patients with atrial fibrillation:insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial[J]. Circulation,2014,130(21):1847-1858.
[31]Sharma A,Hijazi Z,Andersson U,et al. Use of biomarkers to predict specific causes of death in patients with atrial fibrillation[J]. Circulation,2018,138(16):1666-1676.
[32]Hijazi Z,Oldgren J,Andersson U,et al. Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation:Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial[J]. Am Heart J,2017,190:94-103.
[33]Hijazi Z,Oldgren J,Lindb?ck J,et al. The novel biomarker-based ABC (age,biomarkers,clinical history)-bleeding risk score for patients with atrial fibrillation:a derivation and validation study[J]. Lancet,2016,387(10035):2302-2311.
[34]Hijazi Z,Oldgren J,Lindb?ck J,et al. A biomarker-based risk score to predict death in patients with atrial fibrillation:the ABC (age,biomarkers,clinical history) death risk score[J]. Eur Heart J,2018,39(6):477-485.
[35]Hu XF,Zhan R,Xu S,et al. Growth differentiation factor 15 is associated with left atrial/left atrial appendage thrombus in patients with nonvalvular atrial fibrillation[J]. Clin Cardiol,2018,41(1):34-38.
[36]Berg DD,Ruff CT,Jarolim P,et al. Performance of the ABC scores for assessing the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in ENGAGE AF-TIMI 48[J]. Circulation,2019,139(6):760-771.
[37]Liu T,Shao Q,Ng CY,et al. Relation of growth differentiation factor-15 with CHA2DS2-VASc score in Chinese patients with non-valvular atrial fibrillation[J]. Int J Cardiol,2015,184:595-596.

相似文献/References:

[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
　HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(8):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
　DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(8):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
　ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(8):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
　ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(8):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
　HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(8):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
　WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(8):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
　XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(8):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
　ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(8):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
　WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(8):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
　ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(8):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
[11]李谧 李琳.生长分化因子-15在心房颤动中的研究及应用进展[J].心血管病学进展,2020,(7):749.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.0 19]
　LI Mi,LI Lin.Research and Application of Growth Differentiation Factor-15 in Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(8):749.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.0 19]
[12]王昱冕 陈涵 王红.生长分化因子15与心血管疾病出血事件相关性的研究进展[J].心血管病学进展,2022,(10):928.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.015]
　WANG Yumian,CHEN Han.,WANG Hong.Relationship Between Growth Differentiation Factor 15 and Cardiovascular Bleeding Events[J].Advances in Cardiovascular Diseases,2022,(8):928.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.015]

备注/Memo

备注/Memo:
基金项目：国家自然科学基金（31700674）收稿日期：2019-05-13
通讯作者：李蕾，E-mail：drlilei@126.com；崔鸣，E-mail：mingcui@bjmu.edu.cn
更新日期/Last Update: 2020-01-10